Latest News and Press Releases

  Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP) The HIFU...

LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the...

Record full-year 2022 total preliminary unaudited revenue of €55.1 million ($58.0 million) represents an increase of 25.1% over full-year 2021, driven by 58.1% HIFU growth Record Q4 2022 total...

Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL)Positive safety profile with 96.7% of patients with no or non-significant adverse...

Company preliminarily reports nine Focal One Placements in the U.S., including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in...

LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment...

  Study to begin enrolling patients in Q2 2023   Endometriosis represents significant expansion opportunity for Focal One  LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP)...

LYON, France, November 21, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that Marc Oczachowski, Chief Executive Officer, is...

Generated Q3 2022 total revenue of approximately EUR 12.2 million (USD 12.3 million), an increase of 29.7 % as compared to EUR 9.4 million (USD 11.1 million) for Q3 2021; nine-month year-to-date...

Company to host conference call and webcast on Thursday, November 17th at 8:30 am EDT LYON, France, November 2, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies,...